Procalcitonin as a prognostic marker for sepsis: a prospective observational study

BMC Research Notes

Nawaid Khan¹  Sreenivas Vishnubhatla²  Madhuchhanda Das¹  Manish Goel¹  Seema Sood³  Ashutosh Biswas¹  Naval Kishore Vikram¹  Praveen Aggrawal¹  J C Samantaray³  Surendra K Sharma¹  Sanjeev Sinha¹  Saransh Jain¹ 

[1] Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India;Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India;Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India

关键词: C-reactive protein;    Procalcitonin;    Prognosis;    Sepsis;   

Others  :  1131865
DOI  :  10.1186/1756-0500-7-458

 received in 2013-10-30, accepted in 2014-07-07,  发布年份 2014

【 摘 要 】

Background

Procalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in prediction of 28 day mortality in patients of sepsis. Fifty-four consecutive patients of sepsis, severe sepsis and septic shock defined using the 2001 Consensus Conference SCCM/ESICM/ACCP/ATS/SIS criteria from medical Intensive Care Unit (ICU) of a tertiary care center in New Delhi, India were enrolled from July 2011 to June 2013. Procalcitonin (PCT), C-reactive protein (CRP) measurements were recorded on day 1, day 7 and day 28 of follow up.

Results

Procalcitonin value was a better predictor of all-cause short-term mortality than C-reactive protein. Those patients with Procalcitonin levels <7 ng/ml showed higher cumulative survival than those with level [greater than or equal to]7 ng/ml (69.1% vs. 39.5%, p = 0.02). No such effect was observed in relation to C-reactive protein. Procalcitonin levels [greater than or equal to]7 ng/ml predicted mortality with a hazard ratio of 2.6(1.1-6.3).

Conclusions

A Procalcitonin value [greater than or equal to]7 ng/ml obtained at the time of admission to the ICU is a predictor of short-term mortality and thus may allow the identification of those septic patients at increased mortality risk, and help improve their treatment.

【 授权许可】

   
2014 Jain et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J-L, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2001, 2003(29):530-538.
• [2]Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123.
• [3]Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret G-Y: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34:1996-2003.
• [4]Bouadma L, Luyt C-E, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M: Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
• [5]Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H: Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002, 28:1351-1356.
• [6]Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL: Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998, 26:1001-1006.
• [7]Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent J-L, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
• [8]Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
• [9]Grozdanovski K, Milenkovic Z, Demiri I, Spasovska K, Cvetanovska M, Kirova-Urosevic V: Early prognosis in patients with community-acquired severe sepsis and septic shock: analysis of 184 consecutive cases. Prilozi 2012, 33:105-116.
• [10]Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274:968-974.
• [11]Heffner AC, Horton JM, Marchick MR, Jones AE: Etiology of illness in patients with severe sepsis admitted to the hospital from the Emergency Department. Clin Infect Dis 2010, 50:814-820.
• [12]Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
• [13]Bates DW, Sands K, Miller E, Lanken PN, Hibberd PL, Graman PS, Schwartz JS, Kahn K, Snydman DR, Parsonnet J, Moore R, Black E, Johnson BL, Jha A, Platt R: Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis 1997, 176:1538-1551.
• [14]Artero A, Zaragoza R, Camarena JJ, Sancho S, González R, Nogueira JM: Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care 2010, 25:276-281.
• [15]Meng F-S, Su L, Tang Y-Q, Wen Q, Liu Y-S, Liu Z-F: Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality. Clin Biochem 2009, 42:1025-1031.
• [16]Clec’h C, Fosse J-P, Karoubi P, Vincent F, Chouahi I, Hamza L, Cupa M, Cohen Y: Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006, 34:102-107.
• [17]Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, Kolho E, Ruokonen E: Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010, 14:R205.
• [18]Choi SW, Kim H, Kim KH, Shin DW, Park JS, Roh JY, Park JM: Procalcitonin as a prognosis marker for the severe sepsis and septic shock patients in Emergency Department. Korean J Critical Care Med 2011, 26:250.
• [19]Dahaba AA: Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006, 97:503-508.
• [20]Heper Y, Akalın EH, Mıstık R, Akgöz S, Töre O, Göral G, Oral B, Budak F, Helvacı S: Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis 2006, 25:481-491.
• [21]Sauerland S, Hensler T, Bouillon B, Rixen D, Raum MR, Andermahr J, Neugebauer EAM: Plasma levels of procalcitonin and neopterin in multiple trauma patients with or without brain injury. J Neurotrauma 2003, 20:953-960.
• [22]Kocazeybek B, Küçükoğlu S, Oner YA: Procalcitonin and C-reactive protein in infective endocarditis: correlation with etiology and prognosis. Chemotherapy 2003, 49:76-84.
• [23]Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krçmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D: Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004, 10:628-633.
• [24]Schröder J, Staubach K-H, Zabel P, Stüber F, Kremer B: Procalcitonin as a marker of severity in septic shock. Langenbeck’s Arch Surg 1999, 384:33-38.
• [25]Claeys R, Vinken S, Spapen H, Ver Elst K, Decochez K, Huyghens L, Gorus FK: Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002, 30:757-762.
• [26]Briegel J, Möhnle P: International guidelines of the Surviving Sepsis Campaign: Update 2012. Anaesthesist 2013, 62:304-309.
• [27]Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M: Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002, 28:1220-1225.
• [28]Silvestre J, Póvoa P, Coelho L, Almeida E, Moreira P, Fernandes A, Mealha R, Sabino H: Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med 2009, 35:909-913.
• [29]Snider RH Jr, Nylen ES, Becker KL: Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997, 45:552-560.